Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2CRSI S.A. buy melinda

Start price
€5.14
02.05.21 / 50%
Target price
€5.70
02.05.22
Performance (%)
-13.62%
End price
€4.44
01.09.21
Summary
This prediction ended on 01.09.21 with a price of €4.44. The prediction for 2CRSI S.A. disappointed with a performance of -13.62%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
2CRSI S.A. -8.285% -8.285% 123.249% 3.641%
iShares Core DAX® -3.033% -0.013% 11.953% 15.609%
iShares Nasdaq 100 -3.554% -2.546% 30.128% 44.540%
iShares Nikkei 225® -3.938% 2.183% 11.741% 8.345%
iShares S&P 500 -1.517% -0.882% 25.752% 42.388%

According to melinda what are the pros and cons of 2CRSI S.A. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread 2CRSI S.A. diskutieren
Prediction Buy
Perf. (%) -13.62%
Target price 5.700
Change
Ends at

Buy mit Kursziel 5,7

In the thread Trading 2CRSI S.A.
Prediction Buy
Perf. (%) -13.62%
Target price 5.700
Change
Ends at 02.05.22

Buy beendet

Stopped prediction by melinda for 2CRSI S.A.

buy
2CRSI S.A.

Start price
Target price
Perf. (%)
€5.14
17.02.24
-
17.02.25
-14.98%
02.03.24

Could be worthwhile Investment >10% per year
buy
2CRSI S.A.

Start price
Target price
Perf. (%)
€3.90
03.02.24
-
03.02.25
31.79%
17.02.24

Could be worthwhile Investment >10% per year
2CRSI S.A.

Start price
Target price
Perf. (%)
€5.14
07.11.21
€3.00
07.11.22
-16.63%
26.11.21

Could be worthwhile Investment >10% per year
buy
2CRSI S.A.

Start price
Target price
Perf. (%)
€4.44
01.09.21
€5.50
01.09.22
15.77%
07.11.21

Could be worthwhile Investment >10% per year
buy
2CRSI S.A.

Start price
Target price
Perf. (%)
€6.74
23.02.21
€8.50
23.02.22
-23.74%
02.05.21

Could be worthwhile Investment >10% per year